Impact of diabetes on cardiovascular disease: an update

Alessandra Saldanha de Mattos Matheus, Lucianne Righeti Monteiro Tannus, Roberta Arnoldi Cobas, Catia C Sousa Palma, Carlos Antonio Negrato, Marilia de Brito Gomes, Alessandra Saldanha de Mattos Matheus, Lucianne Righeti Monteiro Tannus, Roberta Arnoldi Cobas, Catia C Sousa Palma, Carlos Antonio Negrato, Marilia de Brito Gomes

Abstract

Cardiovascular diseases are the most prevalent cause of morbidity and mortality among patients with type 1 or type 2 diabetes. The proposed mechanisms that can link accelerated atherosclerosis and increased cardiovascular risk in this population are poorly understood. It has been suggested that an association between hyperglycemia and intracellular metabolic changes can result in oxidative stress, low-grade inflammation, and endothelial dysfunction. Recently, epigenetic factors by different types of reactions are known to be responsible for the interaction between genes and environment and for this reason can also account for the association between diabetes and cardiovascular disease. The impact of clinical factors that may coexist with diabetes such as obesity, dyslipidemia, and hypertension are also discussed. Furthermore, evidence that justify screening for subclinical atherosclerosis in asymptomatic patients is controversial and is also matter of this review. The purpose of this paper is to describe the association between poor glycemic control, oxidative stress, markers of insulin resistance, and of low-grade inflammation that have been suggested as putative factors linking diabetes and cardiovascular disease.

Figures

Figure 1
Figure 1
Pathogenesis of cardiovascular disease in diabetes. The mechanisms involved in the pathogenesis of cardiovascular disease in diabetes comprehend epigenetic changes and intracellular metabolic changes that result in oxidative stress, low-grade inflammation, and endothelial dysfunction. CRP: C-reactive protein; FFA: free fatty acids; INOS: inducible nitric oxide synthase; IL-1: interleukin 1; IL-6: interleukin 6; MCP-1: monocyte chemoattractant molecule 1; MMP: matrix metalloproitenase; NF-κB: nuclear factor kappa-β; PAI-1: plasminogen activator inhibitor-1; VCAM-1; vascular cell adhesion molecule-1; VEFG: vascular endothelial growth factor; TNF-α: Tumor necrosis factor-α; INF-γ: Interferon-γ.

References

    1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27(5):1047–1053.
    1. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(supplement 1):533–550.
    1. IDF. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation Diabetes Atlas; 2006.
    1. Negrato CA, Dias JP, Teixeira MF, et al. Temporal trends in incidence of Type 1 diabetes between 1986 and 2006 in Brazil. Journal of Endocrinology Investigation. 2010;33:373–377.
    1. Harris MI. Diabetes in America. 2nd edition. Washington, DC, USA: Government Printing Office; 1995. Summary of national diabetes data group; pp. 1–13. (NIH Publication No. 95-1468).
    1. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:596–615.
    1. Bahia LR, Araújo DV, Schaan BD, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value in Health. 2011;14:S137–S140.
    1. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. Journal of the American College of Cardiology. 2009;53(5):S35–S42.
    1. Kemp TM, Barr ELM, Zimmet PZ, et al. Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab. Diabetes Care. 2005;28(6):1490–1492.
    1. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760–765.
    1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, Ga, USA: 2011.
    1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine. 1998;339(4):229–234.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection. Circulation. 2002;106:3143–3421.
    1. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabetic Medicine. 2009;26(2):142–148.
    1. Al Ghatrif M, Kuo YF, Al Snih S, Raji MA, Ray LA, Markides KS. Trends in Hypertension Prevalence, Awareness, Treatment and Control in Older Mexican Americans, 1993-2005. Annals of Epidemiology. 2011;21(1):15–25.
    1. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care. 2011;34(supplement 1):11–61.
    1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 2000;321(7258):405–412.
    1. DCCT. The diabetes control and complications trial. The New England Journal of Medicine. 1993;329:977–986.
    1. Gomes MB, Gianella D, Faria M, et al. Prevalence of patients with diabetes type 2 within the targets of care guidelines in daily clinical practice: a multicenter study of type 2 diabetes in Brazil. The Revision of Diabetic Studies. 2006;3:73–78.
    1. Gomes MB, Coral M, Cobas RA, et al. Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil Diabetes. Diabetes Research Clinical Practice. 2012;97(1):63–70.
    1. Sociedade Brasileira de Diabetes: Diretrizes da SBD/2011. São Paulo, Brazil: AC Farmaceutica Ltda; 2011.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine. 2008;359(15):1577–1589.
    1. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine. 2009;360(2):129–139.
    1. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. 2008;358(24):2560–2572.
    1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. The New England Journal of Medicine. 2008;358:2545–2559.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine. 2005;353:2643–2653.
    1. Ceriello A, Ihnat MA, Thorpe JE. The "Metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? Journal of Clinical Endocrinology and Metabolism. 2009;94(2):410–415.
    1. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898–918.
    1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. Journal of the American Medical Association. 2001;286(10):1195–1200.
    1. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52(7):1799–1805.
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine. 2001;344(18):1343–1350.
    1. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet. 2009;374:1677–1686.
    1. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis. 1998;141(1):17–30.
    1. Matheus ASDM, Cobas RA, Gomes MB. Dyslipidemias in type 1 diabetes: a current approach. Arquivos Brasileiros de Endocrinologia e Metabologia. 2008;52(2):334–339.
    1. Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. Journal of Clinical Investigation. 2004;114(5):659–668.
    1. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. 2004;364(9435):685–696.
    1. Brown BG, Zhao XQ, Chait A, et al. Sinvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England Journal of Medicine. 2001;345:1583–1592.
    1. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine. 2005;352(14):1425–1435.
    1. Wanner NC, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England Journal of Medicine. 2005;353:238–248.
    1. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.
    1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581–590.
    1. Furtado MV, Polanczyk CA. Prevenção cardiovascular em pacientes com diabetes: revisão baseada em evidências. Arquivos Brasileiros de Endocrinologia e Metabologia. 2007;51(2):312–318.
    1. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005;366(9500):1849–11861.
    1. Keech A, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet. 2007;370(9600):1687–1697.
    1. Diabetes in America. 2nd edition. Bethesda, MD, USA: National Institutes of Health, National Institute of diabetes and Digestive and Kidney Diseases; 1995.
    1. American Diabetes Association. Treatment of hypertension in diabetes. Diabetes Care. 1993;16:1394–1401.
    1. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Journal of the American Medical Association. 1996;276(23):1886–1892.
    1. Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care. 1991;14(supplement 4):13–26.
    1. Turner R, Stratton I, Fright V, Holman R, Manley S, Cull C. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. Journal of Hypertension. 1993;11(3):309–317.
    1. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(supplement 1):S11–S63.
    1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Journal of the American Medical Association. 2003;289(19):2560–2572.
    1. Maneia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension. 2009;27(11):2121–2158.
    1. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007;370(9590):829–840.
    1. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Medical Journal. 2000;321(7258):412–419.
    1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications intype 2 diabetes: UKPDS 38. British Medical Journal. 1998;317:p. 703.
    1. Roccella EJ. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine. 1997;157(21):2413–2446.
    1. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England Journal of Medicine. 2010;362:1575–1585.
    1. Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF. Oxidative stress and vascular damage in hypertension. Current Opinion in Nephrology and Hypertension. 2001;10(2):247–255.
    1. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart. 2004;90(5):491–493.
    1. Goligorsky MS. Making sense out of oxygen sensor. Circulation Research. 2000;86(8):824–826.
    1. Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(8):1903–1911.
    1. Fukui T, Lassegue B, Kai H, et al. Cytochrome b558 alpha subunit cloning and expression in rat aortic smooth muscle cells. Biochimica et Biophysica Acta. 1995;231:215–219.
    1. Chabrashvili T, Tojo A, Onozato ML, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39(2 I):269–274.
    1. Azumi H, Inoue N, Takeshita S, et al. Expression of NADH/NADPH oxidase p22(phox) in human coronary arteries. Circulation. 1999;100(14):1494–1498.
    1. Greiber S, Munzel T, Kastner S, et al. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney International. 1998;53:654–663.
    1. Jones SA, Hancock JT, Jones OTG, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. Journal of the American Society of Nephrology. 1995;5(7):1483–1491.
    1. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation. 1998;97(2):135–137.
    1. Van Heerebeek L, Meischl C, Stooker W, Meijer CJLM, Niessen HWM, Roos D. NADPH oxidase: new source of reactive oxygen species in the vascular system? Journal of Clinical Pathology. 2002;55(8):561–568.
    1. Ihnat MA, Thorpe JE, Kamat CD, et al. Reactive oxygen species mediate a cellular “memory” of high glucose stress signaling. Diabetologia. 2007;50:1523–1531.
    1. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. Journal of Physiology and Pharmacology. 2002;53(4 I):515–524.
    1. Ballinger SW, Patterson C, Yan CN, et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circulation Research. 2000;86(9):960–966.
    1. Ceriello A, Morocutti A, Mercuri F, et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes. 2000;49(12):2170–2177.
    1. Marra G, Cotroneo P, Pitocco D, et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care. 2002;25(2):370–375.
    1. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian men. Clinical Chemistry. 2008;54(2):273–284.
    1. Waring WS, McKnight JA, Webb DJ, Maxwell SRJ. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006;55(11):3127–3132.
    1. Matheus ASM, Tibiriçá E, da Silva PB, et al. Uric acid levels are associated with microvascular endothelial dysfunction in patients with type 1 diabetes. Diabetic Medicine. 2011;28(10):1188–1193.
    1. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes. 2008;57(6):1702–1706.
    1. Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus-natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. European Journal of Internal Medicine. 2001;23(7):628–632.
    1. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. Journal of the American College of Cardiology. 2002;40(11):1984–1990.
    1. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58(12):2718–2725.
    1. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine. 2008;205(10):2409–2417.
    1. Millis RM. Epigentics and hypertension. Current Hypertension Reports. 2011;13:21–28.
    1. Stoger R. Epigenetics and obesity. Pharmacogenomics. 2008;9:1851–1860.
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
    1. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation. 2006;116(7):1793–1801.
    1. Vicenova B, Vopalensky V, Burysek L, et al. Emerging role of interleukin-1 in cardiovascular disease. Physiology Research. 2009;58:481–498.
    1. Ferrarezi DAF, Cheurfa N, Reis AF, Fumeron F, Velho G. Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences. Arquivos Brasileiros de Endocrinologia e Metabologia. 2007;51(2):153–159.
    1. Ait-Oufella H, Taleb S, Mallat Z, et al. Recent advances on the role of cytokines in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:969–979.
    1. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. Journal of Clinical Investigation. 2005;115(5):1111–1119.
    1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America. 2004;88(4):787–835.
    1. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation Research. 2006;98(5):596–605.
    1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 2001;286(3):327–334.
    1. Chait A, Chang YH, Oram JF, Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? Journal of Lipid Research. 2005;46(3):389–403.
    1. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine. 2002;8:1288–1295.
    1. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circulation Research. 2007;101(6):545–559.
    1. Basha B, Samuel SM, Triggle CR, et al. Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress? Experimental Diabetes Research. 2012;2012:14 pages.481840
    1. Romano M, Pomilio M, Vigneri S, et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care. 2001;24(9):1674–1678.
    1. Hadi HAR, Al Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management. 2007;3(6):853–876.
    1. Yan J, Tie G, Park B, Yan Y, Nowicki PT, Messina LM. Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells. Journal of Vascular Surgery. 2009;50(6):1412–1422.
    1. Hazel L, Kenneth A, Roebuck O. Oxidant stress and endothelial cell dysfunction. American Journal of Physiology. 2001;280:C719–C741.
    1. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes care. 2009;32:S314–321.
    1. Skyrme-Jones RAP, O’Brien RC, Luo M, Meredith IT. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. Journal of the American College of Cardiology. 2000;35(2):292–299.
    1. Gomes MB, Matheus ASM, Tibiriçá E. Evaluation of microvascular endothelial function in patients with type 1 diabetes using laser-Doppler perfusion monitoring: which method to choose? Microvascular Research. 2008;76(2):132–133.
    1. Tibiriçá E, Rodrigues E, Cobas RA, et al. Endothelial function in patients with type 1 diabetes evaluated by skin capillary recruitment. Microvascular Research. 2007;73:107–112.
    1. Koitka A, Abraham P, Bouhanick B, et al. Impaired pressure-induced vasodilation at the foot in young adults with type 1 diabetes. Diabetes. 2005;53:721–725.
    1. Chan NN, Vallance P, Colhoun HM. Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(6):1048–1054.
    1. Schram MT, Chaturvedi N, Schalkwijk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care. 2003;26(7):2165–2173.
    1. Khan F, Elhadd TA, Greene SA, Belch JJF. Impaired skin microvascular function in children, adolescents, and young adults with type I diabetes. Diabetes Care. 2000;23(2):215–220.
    1. Gomes MB, Cobas RA, Nunes E, et al. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice. 2009;85:61–68.
    1. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55(3):774–779.
    1. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling and wound healing. International Journal of Vascular Medicine. 2012;2012:30 pages.918267
    1. Stalker TJ, Skvarka CB, Scalia R. A novel role for calpains in the endothelial dysfunction of hyperglycemia. The FASEB Journal. 2003;17(11):1511–1513.
    1. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101(15):1780–1784.
    1. Rolim LC, Sá JR, Chacra AR, Dib SA. Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis. Arquivos brasileiros de cardiologia. 2008;90(4):e24–31.
    1. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387–397.
    1. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabetic Medicine. 2011;28(6):643–651.
    1. Lampert R, Bremner JD, Su S, et al. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. American Heart Journal. 2008;156(4):759–767.
    1. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care. 2010;33(3):652–657.
    1. Schmid H. Impacto cardiovascular da neuropatia autonômica do diabetes mellitus. Arquivos Brasileiros de Endocrinologia e Metabologia. 2007;51:232–243.
    1. Young LH, Wackers FJT, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes the DIAD study: a randomized controlled trial. Journal of the American Medical Association. 2009;301(15):1547–1555.
    1. Frans JTH, Wackers FJT, Young LH, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects. Diabetes Care. 2004;27:1954–1961.
    1. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. The New England Journal of Medicine. 2007;356:1503–1516.
    1. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. The New England Journal of Medicine. 2009;360:2503–2515.
    1. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30(10):2729–2736.
    1. Fox CS, Sullivan L, D’Agostino RB, Wilson PWF. The significant effect of diabetes duration on coronary heart disease mortality: the framingham heart study. Diabetes Care. 2004;27(3):704–708.
    1. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation. 2000;101(8):850–855.
    1. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. American Heart Journal. 2001;141(3):375–382.
    1. Jasinowodolinski D, Szarf G. Calcium score in the cardiovascular evaluation of the diabetic patient. Arquivos Brasileiros de Endocrinologia e Metabologia. 2007;51(2):294–298.
    1. Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. American Journal of Cardiology. 2001;87(12):1335–1339.
    1. Janowitz WR, Agatston AS, Kaplan G, Viamonte M. Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. American Journal of Cardiology. 1993;72(3):247–254.
    1. Malik S, Budoff MJ, Katz R, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes. The multi-etnic study of atherosclerosis. Diabetes Care. 2011;4:2285–2290.
    1. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. Journal of the American College of Cardiology. 2010;56(25):e50–e103.
    1. Irie Y, Katakami N, Kaneto H, et al. Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. Atherosclerosis. 2012;221(2):438–444.
    1. Polak JF, Backlund JYC, Cleary PA, et al. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes. 2011;60(2):607–613.
    1. Mohler ER. Peripheral arterial disease: identification and implications. Archives of Internal Medicine. 2003;163(19):2306–2314.
    1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional. Journal of the American College of Cardiology. 2006;47(6):1239–1312.
    1. Doza B, Kaur M, Chopra S, et al. Cardiovascular risk factors and distributions of the ankle brachial index among type 2 diabetes mellitus patients. International Journal of Hypertension. 2012;2012:6 pages.485812

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir